> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sanofi Scraps Phase 2 Multiple Sclerosis Study
- URL: https://www.fdaweb.com/sanofi-scraps-phase-2-multiple-sclerosis-study/
- Published: 2024-10-11T12:00:00.000Z
- Updated: 2026-09-14T14:43:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157972

Denali Therapeutics says its strategic partner Sanofi has decided to discontinue a [Phase 2 study](https://www.clinicaltrials.gov/study/NCT05630547?intr=SAR443820&rank=3&ref=fdaweb.com#more-information) evaluating the safety and efficacy of oditrasertib (SAR443820/DNL788) on serum neurofilament light chain levels in participants with multiple sclerosis. In a SEC filing, Denali says the study failed to meet primary and key secondary endpoints. Oditrasertib is described as a selective, orally bioavailable, brain-penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). Protein kinase RIPK1 controls the balance between cell life and death, and it’s a key regulator of inflammation, apoptosis, and necroptosis, according to a [journal article](https://www.nature.com/articles/s41573-020-0071-y?ref=fdaweb.com#:~:text=Receptor%2Dinteracting%20serine/threonine%2Dprotein%20kinase%201%20%28RIPK1%29%20is%20a,range%20of%20animal%20models%20of%20human%20diseases.) in *Nature*.